Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec.
Felix Friedrich ReichelImmanuel SeitzFabian WozarSpyridon DimopoulosRonja JungMelanie KempfSusanne KohlFriederike Charlotte KortümSaskia OttLisa PohlKrunoslav StinglKarl Ulrich Bartz-SchmidtKatarina StinglM Dominik FischerPublished in: The British journal of ophthalmology (2022)
Subretinal injection of VN can lead to RPE atrophy with consequent photoreceptor loss in and outside of the bleb area. Fundus autofluorescence is an important tool to monitor atrophic changes in patients after gene therapy. Interestingly, while areas of atrophy also included central areas, the functional benefits of the treatment did not appear to be affected and remained stable.